YK012

Phase 2Small molecule

EExcyte Biopharma Ltd

YK012 is one of 86 small molecule programs targeting Membranous Nephropathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Membranous NephropathyNot yet recruiting

Refractory B-Cell Non-Hodgkin LymphomaRecruiting

Systemic Lupus ErythematosusRecruiting

B-Cell Acute Lymphoblastic LeukemiaRecruiting

Membranous NephropathyPhase 1

Not yet recruiting

Refractory B-Cell Non-Hodgkin LymphomaPhase 1

Recruiting

Systemic Lupus ErythematosusPhase 2

Recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

134 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Medrol

Pfizer

Phase 3

5 3

Rinvoq

AbbVie

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

12 5

Gazyva

Roche

Phase 3

2 6

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

3 7

Rapamune

PPrism Pharmaceuticals

Phase 3

1 8

Ianalumab

Novartis

Phase 3

3 9

Fludara

Sanofi

Phase 2

6 10

Glucocorticoid

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT06580301

Q4 2027

Phase 1Recruiting

Membranous Nephropathy

NCT06982729

Q1 2028

Phase 1Not yet recruiting

Membranous Nephropathy

NCT07234474

Q4 2028

Phase 1/2Recruiting

Systemic Lupus Erythematosus

NCT07010835

Phase 1Recruiting

Refractory B-Cell Non-Hodgkin Lymphoma

NCT06565689

Clinical

Trials by Indication[1]

Membranous Nephropathy2 trials

Study of YK012 in Primary Membranous Nephropathy

Recruiting·EExcyte Biopharma Ltd·Phase 1·NCT06982729·72 enrolled

A Phase I Study of YK012 in Primary Membranous Nephropathy

Not yet recruiting·EExcyte Biopharma Ltd·Phase 1·NCT07234474·66 enrolled

Systemic Lupus Erythematosus1 trial

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Recruiting·EExcyte Biopharma Ltd·Phase 1/2·NCT07010835·189 enrolled

B-cell acute lymphoblastic leukemia1 trial

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Recruiting·EExcyte Biopharma Ltd·Phase 1/2·NCT06580301·46 enrolled

Refractory B-Cell Non-Hodgkin Lymphoma1 trial

A Multi-center, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting·EExcyte Biopharma Ltd·Phase 1·NCT06565689·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for YK012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YK012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YK012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Excyte Biopharma Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EExcyte Biopharma Ltd

YK012

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Membranous Nephropathy2 trials

Systemic Lupus Erythematosus1 trial

B-cell acute lymphoblastic leukemia1 trial

Refractory B-Cell Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News